News & Videos - EUROAPI - English

Press Release Paris – October 16, 2024 – Olivier Falut has been appointed EUROAPI’s Chief Financial Officer, effective October 17, 2024, and will be a member of the Executive Committee. He is taking over from Evelyne Nguyen, who will remain within the company until the end of October to ensure a smooth transition. “I am delighted to welcome Olivier, a seasoned Chief Financial Officer with extensive experience in the industrial sector. He will play a decisive role in implementing our...

Press Release Paris - 15 October 2024 - EUROAPI today announces the closing of the refinanced Credit Revolving Facility (RCF) and the Perpetual Deeply Subordinated Hybrid Bond subscribed by Sanofi, thus completing the financing of its FOCUS-27 strategic plan. About EUROAPI EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’ and patients’ needs around the world. We are a leading player in active pharmaceutical ingredients with approximately 200...

Press Release Paris, 30th July 2024 Net Sales down 9.6% year-on-year – Core EBITDA margin at 10.6% Accelerated commercial momentum with clients other than Sanofi, with Net Sales up 2.9%, excluding the Brindisi site, where production was temporarily suspended Enhanced effectiveness across the entire organization, with sizeable improvements in industrial efficiencies €10 million Free Cash Flow before financing, driven by strengthened financial discipline FY 2024 guidance confirmed " Our H1...

Press Release A 5-year manufacturing contract to support the FOCUS-27 project sales trajectory This contract highlights EUROAPI’s know-how and the reliability of its premium Contract Manufacturing Organization services to customers Paris – May 23, 2024 – EUROAPI announces today that it has entered into a Contract Manufacturing Organization (CMO) agreement with a global animal health company. As part of this collaboration, EUROAPI will supply its client with a key veterinary product. The...

Press Release Paris – April 5, 2024 – EUROAPI announces the publication of its 2023 Universal Registration Document, filed with the French Autorité des marchés financiers (AMF) on April 5, 2024. The 2023 Universal Registration Document includes in particular: The annual financial report; The Board of Directors’ corporate governance report; The information about social, environmental, and societal responsibility (including the extra-financial performance declaration); The statutory...

Regulatory News: EUROAPI (Paris:EAPI) posted today its 2023 Condensed Half-Year Consolidated Financial Statements for the six months ended June 30, 2023. This document is available for consultation and downloading on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports . This report includes notably the 2023 half-year activity report, the summary consolidated financial statements on 30 June 2023, and the Statutory Auditors’ review report on the...

Regulatory News: EUROAPI (Paris:EAPI): €496.6 million in Net Sales, up 2.6% 1 API Solutions (+0.2% sales growth, +1.9% with Other Clients, and -1.2% with Sanofi) pursued the deployment of its commercial roadmap, with 35 new clients added in H1 in both small and large molecules, the acceleration of the cross-selling strategy, and pricing optimization. H1 sales included the residual impact of the suspension of prostaglandin production in Budapest, which fully resumed in mid-April (approximately...

Regulatory News: EUROAPI (Paris:EAPI) is further addressing health sovereignty concerns in France and Europe. The Group is announcing several initiatives to increase its production capacities for several active pharmaceutical ingredients listed as essential medicines by the French authorities. EUROAPI’s Francopia 1 subsidiary dedicated to controlled substances 2 , will invest in R&D activities on its Vertolaye (Puy-de-Dôme) site. These R&D activities aim to increase EUROAPI’s production of...

Regulatory News: EUROAPI (Paris:EAPI) announces a €50 million capex investment for the installation of a new state-of-the-art production plant at its Budapest site. The project will be focused on the debottlenecking of the current capacity and the construction of new multi-purpose manufacturing equipment that will more than double the overall prostaglandin capacity of the Budapest site by 2027 in two phases: 2023-2025 (approximately 2/3 of the total investment) and 2026-2027. Prostaglandin is...

Regulatory News: The Combined General Shareholders’ Meeting of EUROAPI (Paris:EAPI) was held on May 11, 2023 in Paris, under the chairwomanship of Viviane Monges, and was attended by all directors. All resolutions put forth to a vote were adopted by the shareholders. The General Meeting approved the unconsolidated and consolidated financial statements for the year 2022, the ratification of the co-option of Mattias Perjos as an independent director and all the compensation arrangements of the...

Regulatory News: The Board of Directors of EUROAPI (Paris:EAPI) proposes the ratification of the appointment by co-optation of a new director, Géraldine Leveau, as of May 10, 2023, replacing Jean-Christophe Dantonel, who resigned from his directorship. Her appointment will be proposed to ratification at the Annual General Meeting approving the financial statements as of December 31, 2023. Géraldine Leveau has been appointed Deputy Secretary General for Investment in 2021 by the French Prime...

Regulatory News: EUROAPI announces today the implementation of an initial 4-year manufacturing agreement with Novéal, an integral part of the L’Oréal Group with a focus on developing eco-responsible processes and guaranteeing exclusive, high-performance ingredients to sustainably meet the beauty needs of consumers around the world. As part of this collaboration, EUROAPI will develop and industrialize the manufacturing process of innovative cosmetic ingredients through its Contract...

Regulatory News: EUROAPI (Paris:EAPI) announces the publication of the first amendment to its 2022 Universal Registration Document, approved by the French Autorité des marchés financiers (AMF) on April 13, 2023, under number R.23-009. This Amendment has been approved by the AMF on April 25, 2023, under number R. 23-015. This document is available on EUROAPI’s website: https://www.euroapi.com/en/investors/regulatory-information/financial-reports and on the AMF website ( www.amf-france.org )....

Regulatory News: EUROAPI (Paris:EAPI) announces the publication of its 2022 Universal Registration Document, approved by the French Autorité des marchés financiers (AMF) on April 13, 2023, under number R.23-009. The 2022 Universal Registration Document includes in particular: The annual financial report; The Board of Directors’ corporate governance report; The information about social, environmental, and societal responsibility (including the extra-financial performance declaration); the...

Regulatory News: EUROAPI (Paris:EAPI): 2022 highlights 1 €976.6 million Net Sales, up 8.5% , driven by solid performance in both CDMO (+18.3%), and API Solutions (+5.3%). Large Molecules’ Net Sales up 79.9% to €98.4 million. API Solutions performance driven by both existing and new clients. More than 30 clients added in 2022 - extension of a material multiyear contract with a major Japanese pharmaceutical group. Robust commercial activity in CDMO with 79 projects at the end of 2022 and 230...

Regulatory News: EUROAPI (Paris:EAPI) progressively restarted prostaglandin production at its Budapest site on January 19. As communicated to the market in its press release of December 7, 2022, EUROAPI identified certain Good Manufacturing Practices deficiencies related to production documentation during an internal assessment and decided, out of an abundance of caution, to proactively and temporarily suspend prostaglandin activities at its Budapest site. The Group has built and successfully...

Regulatory News: The Board of Directors of EUROAPI (Paris:EAPI) proposes the ratification of the appointment by co-optation of a new independent director, Mattias Perjos, as of January 11, 2023. Corinne Le Goff, after serving as an independent member on the Board of Directors since May 6, 2022, has resigned from her directorship as of January 11, 2023. Corinne Le Goff has been appointed as President and Chief Executive Officer of Imunon. Mattias Perjos is currently President and Chief Executive...

Regulatory News: EUROAPI (Paris:EAPI) announces that its Board of Directors has approved a €40 million investment for the implementation of a new production technology dedicated to vitamin B12 at its site in Saint-Aubin-lès-Elbeuf (Seine-Maritime, France). The project should enable EUROAPI to increase its manufacturing capacity by 2025 while reducing its environmental footprint. This investment benefits from a total financial support of €7.9 million, from the French Government within the...

Regulatory News: In the context of a temporary suspension of some of its production activities at its Budapest site, EUROAPI (Paris:EAPI) today provides an update on its financial guidance for 2022. During an internal assessment, the Group identified some Good Manufacturing Practices deficiencies related to documentation management. These are associated with Production Records for certain prostaglandin products which are manufactured in a segregated production unit at its Budapest site. Upon...

Regulatory News: EUROAPI (Paris:EAPI) announces an initial €18 million investment for the installation of new state-of-the-art manufacturing equipment at its Frankfurt site. With this project, EUROAPI expects to meet the growing Contract Development and Manufacturing Organization (CDMO) demand for peptides and oligonucleotides. It will bolster the company’s German operations and reinforce EUROAPI’s commitment to advancing innovation in differentiated segments of active pharmaceutical...